Abstract:Amyloid beta (A beta) peptides in cerebrospinal fluid are extensively estimated for identification of Alzheimer's disease (AD) as diagnostic biomarkers. Unfortunately, their pervasive application is hampered by interference from A beta propensity of self-aggregation, nonspecifically bind to surfaces and matrix proteins, and by lack of quantitive standardization. Here we report on an alternative Ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) method for simultaneous measurement of human amyloid beta peptides A beta 1-38, A beta 1-40 and A beta 1-42 in cerebrospinal fluid (CSF) using micro-elution solid phase extraction (SPE). Samples were pre-processing by the mixed-mode micro-elution solid phase extraction and quantification was performed in the positive ion multiple reaction monitoring (MRM) mode using electrospray ionization. The stable-isotope labeled A beta peptides N-15(51)- A beta 1-38, N-15(53)- A beta 1-40 and N-15(55)- A beta 1-42 peptides were used as internal standards. And the artificial cerebrospinal fluid (ACSF) containing 5% rat plasma was used as a surrogate matrix for calibration curves. The quality control (QC) samples at 0.25, 2 and 15 ng/mL were prepared. A "linear" regression (1/x(2) weighting): y = ax + b was used to fit the calibration curves over the concentration range of 0.1-20 ng/mL for all three peptides. Coefficient of variation (CV) of intra-batch and inter-batch assays were all less than 6.44% for A beta 1-38, 6.75% for A beta 1-40 and 10.74% for A beta 1-42. The precision values for all QC samples of three analytes met the acceptance criteria. Extract recoveries of A beta 1-38, A beta 1-40 and A beta 1-42 were all greater than 70.78%, both in low and high QC samples. The stability assessments showed that QC samples at both low and high levels could be stable for at least 24 h at 4 degrees C, 4 h at room temperature and through three freeze-thaw cycles without sacrificing accuracy or precision. And no significant carryover effect was observed. This validated UHPLC/MS/MS method was successfully applied to the quantitation of A beta peptides in real human CSF samples. Our work may provide a reference method for simultaneous quantitation of human A beta 1-38, A beta 1-40 and A beta 1-42 from CSF.

Quantification of Alzheimer Amyloid Β Peptides Ending at Residues 40 and 42 by Novel ELISA Systems

Salivary Aβ1–42 May Be a Quick-Tested Biomarker for Clinical Use in Alzheimer’s Disease: a Meta-Analysis

Quantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applications

Quantitative Measurement of Cerebrospinal Fluid Amyloid-β Species by Mass Spectrometry

EXPRESS: New plasma LC-MS/MS assays for the quantitation of beta-amyloid peptides and identification of apolipoprotein E proteoforms for Alzheimer's disease risk assessment.

An LC-MS/MS-based platform for the quantification of multiple amyloid beta peptides in surrogate cerebrospinal fluid

An Enzyme-Linked Immunosorbent Assay To Compare The Affinity Of Chemical Compounds For Beta-Amyloid Peptide As A Monomer

Regenerable and Simultaneous Surface Plasmon Resonance Detection of Aβ(1−40) and Aβ(1−42) Peptides in Cerebrospinal Fluids with Signal Amplification by Streptavidin Conjugated to an N-Terminus-Specific Antibody

Competitive Electrochemical Immunoassay For Detection Of Beta-Amyloid (1-42) And Total P-Amyloid Peptides Using Beta-Aminophenol Redox Cycling

An UHPLC–MS/MS Method for Simultaneous Quantification of Human Amyloid Beta Peptides Aβ1-38, Aβ1-40 and Aβ1-42 in Cerebrospinal Fluid Using Micro-Elution Solid Phase Extraction

Competitive electrochemical immunoassay for detection of β-amyloid (1-42) and total β-amyloid peptides using p-aminophenol redox cycling.

An enzyme-linked immunosorbent assay to compare the affinity of chemical compounds for β-amyloid peptide as a monomer

An optimized UPLC-MS/MS method for human plasma amyloid-β 42 and 40 measurement and application in Alzheimer's disease diagnosis

Mass Spectrometry–Based Candidate Reference Measurement Procedure for Quantification of Amyloid-β in Cerebrospinal Fluid

In Situ Monitoring the Aggregation Dynamics of Amyloid-β Protein Aβ42 in Physiological Media Via a Raman-Based Frequency Shift Method.

A screening UHPLC–MS/MS method for the analysis of amyloid peptides in cerebrospinal fluid of preclinical species

Strategies for Measuring Concentrations and Forms of Amyloid-Β Peptides

Detection of Amyloid-β(1–42) Aggregation With a Nanostructured Electrochemical Sandwich Immunoassay Biosensor

Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-β1–42 and τ Proteins as Alzheimer Disease Biomarkers

Accurate characterization of β-amyloid (Aβ40, Aβ42) standards using species-specific isotope dilution by means of HPLC-ICP-MS/MS

Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques